Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology
On Monday May 18, 2009, 8:30 am EDT
SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq: RDEA - News) today announced that it will present data from multiple Phase 1 studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
Data will be presented on the safety, pharmacokinetics and uric acid-lowering effects of the administration of single-, and multiple-ascending-doses of RDEA594 in normal healthy volunteers, as well as data from studies designed to assess the potential for drug-drug interactions with RDEA594 and other renally-cleared drugs.
Presentation details are as follows:
Date/Time: Thursday, June 11, 2009 from 11:45 AM – 1:30 PM CET
Poster Title: Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of
RDEA594, A Novel Uricosuric Agent, In Healthy Volunteers
Abstract Number: THU0451
Location: Bella Center Copenhagen – Poster Area
Date/Time: Thursday, June 11, 2009 from 11:45 AM – 1:30 PM CET
Poster Title: RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important
Renal Transporters, OAT1 and OAT3
Abstract Number: THU0452
Location: Bella Center Copenhagen – Poster Area
About RDEA594
RDEA594 is our lead product candidate for the treatment of hyperuricemia and gout. RDEA594 is an inhibitor of the URAT1 transporter in the kidney, which is responsible for the regulation of uric acid levels. Over 300 people have safely received RDEA594, either by direct administration or through administration of RDEA806, its prodrug.
surf's up......crikey
